• Fluoxetine HCl Beyond Serotonin-First Models

  2026-09-25

  Fluoxetine HCl is a useful serotonergic probe—but its value in translational neuroscience depends on asking what the experiment can and cannot establish. Developmental SSRI findings point to persistent, motivation-selective changes involving nucleus accumbens mu-opioid receptors, making a case for separating drug target engagement from circuit-level outcomes.

• Amitriptyline HCl: Practical Research Workflow

  2026-09-25

  Amitriptyline HCl (SKU B2231) provides a documented small-molecule perturbation for receptor and signaling studies, with product-specified potency, solubility, and storage information to guide setup. Use it in controlled neuropharmacology experiments, not as a selective probe or standalone evidence of disease-model efficacy without orthogonal validation.

• 6-OHDA Hydrochloride: A Model-Design Guide

  2026-09-24

  Explore how 6-OHDA hydrochloride creates catecholaminergic injury models and how to interpret its effects without confusing cellular uptake with functional outcomes. This guide also draws a careful assay-design lesson from research on nanoparticle protein coronas.

• SAR131675 VEGFR-3 Inhibitor: Applied Workflows

  2026-09-24

  Use SAR131675 to probe VEGFR-3-dependent endothelial signaling with nanomolar biochemical and cell-based readouts, while separating receptor-specific effects from broader angiogenic phenotypes. This workflow emphasizes dose selection, formulation checks, and careful interpretation of a separate nicotine–kidney disease review used as a model for endpoint design—not evidence of a kidney indication.

• Adefovir Workflows for HBV and OAT1 Research

  2026-09-23

  Build reproducible Adefovir experiments around two distinct strengths: HBV polymerase inhibition and OAT1 substrate behavior. A case report of phosphate-wasting bone disease adds a practical reminder to pair antiviral work with renal and mineral-metabolism questions when those are within scope.

• CBD, Orofacial Pain, and Affective Circuitry

  2026-09-23

  A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) reduces both inflammatory orofacial nociception and pain-associated affective deficits in mice through coordinated peripheral endocannabinoid, central pain-network, and serotonergic mechanisms. Its integrated behavioral, biochemical, and fiber-photometry design provides a useful framework for studying pain as a sensory, emotional, and cognitive disorder rather than as an isolated reflex.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-09-22

  Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, assay controls, and stability handling; the reagent is for scientific research workflows only and should not be used for diagnostic, therapeutic, or medical purposes.

• Amikacin Sulfate: Targeting NTM Granulomas

  2026-09-22

  Amikacin Sulfate is more than a bactericidal aminoglycoside: it is a platform for asking how antibiotic exposure can be concentrated where Mycobacterium avium persists. This article connects ribosomal mechanism, dendritic-cell delivery, experimental controls, and translational decision-making for researchers developing more precise NTM therapies.

• Escitalopram Workflows for Serotonergic Research

  2026-09-21

  Build reproducible Escitalopram assays around transporter selectivity, vehicle control, and phenotype-aware analysis. This workflow connects 5-HT reuptake inhibition with practical antidepressant research and the anxious-depression findings reported in a controlled augmentation study.

• VEGFC–Macrophage Signaling in NASH Fibrosis

  2026-09-21

  This study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes inflammatory macrophage recruitment and limits macrophage phenotypic resolution during high-fat diet-induced hepatic fibrosis. Pharmacological VEGFR-3 inhibition, hepatocyte-specific Vegfc deletion, human clinical data, and cell-based experiments together position VEGFC suppression as a mechanistic component of naringin-mediated protection.

• Targeted Amikacin Delivery into Mycobacterial Granulomas

  2026-09-20

  Montes-Worboys and colleagues developed a dendritic-cell carrier system to direct fluorescently traceable amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof of localization and supports cell-mediated delivery as a strategy for increasing antibiotic exposure at infected tissue, while stopping short of demonstrating superior therapeutic efficacy.

• Amitriptyline HCl in Neuropharmacology Workflows

  2026-09-19

  Amitriptyline HCl provides a practical multi-receptor perturbation tool for receptor signaling, blood-brain barrier, and neuropharmacology assays. This guide combines concentration planning, fresh-solution handling, and lipidomics-inspired controls to improve mechanistic interpretation without overstating evidence from unrelated disease models.

• Amikacin Sulfate: Reliable Cell Assays

  2026-09-18

  This scenario-driven guide shows how Amikacin Sulfate (SKU C8696) can support more interpretable viability, proliferation, and intracellular killing experiments. It connects concentration selection, host-cell compatibility, CFU endpoints, storage, and supplier evaluation to published amikacin data.

• Adefovir (GS-0393): From Mechanism to Translation

  2026-09-18

  A translational perspective on Adefovir (GS-0393) that connects HBV DNA polymerase inhibition with OAT1-mediated renal pharmacokinetics, experimental design, and reproducible research workflows.

• Amitriptyline HCl: Protocol and QC Guide

  2026-09-17

  Amitriptyline HCl (SKU B2231) provides a defined small-molecule reference for receptor-inhibition profiling, solution preparation, and controlled neuropharmacology research workflows. It is intended for assay development and in vitro mechanistic studies, not as evidence of clinical efficacy or a substitute for assay-specific validation.

7938 records 1/530 page Next 12345 下5页 Last page